News Articles

January 23, 2023 – Woman’s Doctor: Study Says Women Have Higher Risk of Stomach Cancers

In this Woman’s Doctor segment, we take a closer look at stomach cancer. It’s a disease increasing among Americans under 50, particularly women. That’s according to a study by the National Cancer Institute which tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and found the study result a bit surprising and he joins us with more information.

Read more>

January 17, 2023 – Study: Stomach Cancer Increases Among Younger Americans

The rate of stomach cancer is increasing among Americans under 50, particularly women, according to a study by the National Cancer Institute. Researchers tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center surgical oncologist Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and found the study results a bit surprising. The study also found women are affected more by autoimmune diseases, which can also lead to cancer.

Read more>

January 11, 2023 – ASCO Guidelines Shine Light on Treatments for Gastroesophageal Cancer

The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer following a systemic review of 18 randomized controlled trials by an expert panel.

Read more>

January 2, 2023 – Zolbetuximab and Chemotherapy Combination Demonstrates Positive Results for Some Patients with Gastric Cancers, According to Results from Phase 3 Trial

Zolbetuximab in combination with a chemotherapy regimen including capecitabine and oxaliplatin (CAPOX) demonstrated positive results in patients with HER2-negative locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers, according to results of GLOW, a phase 3 clinical trial.

Read more>

December 22, 2022 – Associations Between CDH1 Germline Variants and Hereditary Diffuse Gastric Cancer Syndrome Cancer Phenotypes

In a study reported in The Lancet Oncology, Garcia-Pelaez and colleagues found that presence of germline truncating pathogenic variants or likely pathogenic variants of CDH1 were associated with hereditary diffuse gastric cancer (HDGC) tumor risk syndrome–related cancer phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), with no apparent association of these phenotypes with CDH1 missense variants of unknown significance (VUS). Expansion of criteria for the lobular breast cancer phenotype was proposed to account for cases associated with CDH1 PV/LPVs that did not meet the 2020 clinical criteria for HDGC.

Read more> 

December 20, 2022 – U.S. Minorities Overly Affected By Stomach Cancer: How to Avoid

Stomach (gastric) cancer is not very prevalent in the United States, with only 1.5% of all new cancer diagnoses representing the disease. Despite this, data shows minorities — especially Asian Americans — are more vulnerable to stomach cancer.

A new study from Stanford headed by Joo Ha Hwang, MD, Ph.D., professor of gastroenterology and hepatology at Stanford Medicine, explores the prevalence of stomach cancer in U.S. minority communities. Hwang concludes Asian Americans, specifically Korean Americans, are more likely to obtain gastric cancer.

Read more> 

December 19, 2022 – Enhertu Approved in the EU for Patients with Previously Treated HER2-Positive Advanced Gastric Cancer

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Read more>


Re: Consumer Participation on Scientific Peer Review Panels 

For Immediate Press Release: 


The Congressionally Directed Medical Research Programs’ (CDMRP), Peer Reviewed Cancer Research Program (PRCRP) consumer advocate Amy Jacobs recently participated in the evaluation of research applications submitted to the PRCRP. Amy Jacobs was nominated for participation in the program by Debbie’s Dream Foundation: Curing Stomach Cancer.  As a consumer reviewer, she was a full voting member, (along with prominent scientists) at meetings to help determine how the $110 million appropriated by Congress for Fiscal Year 2020 will be spent on cancer research. 

Consumer reviewers are asked to represent the collective view of patients by preparing comments on the impact of the research on issues such as diagnosis, treatment, and quality of life. When commenting on serving as a consumer reviewer, Amy said that, “this was my second time serving as a Consumer Advocate. It is such a high honor and privilege to participate among these brilliant scientists and medical professionals, giving a Stage 4 Stomach Cancer patient’s insight and views for the subject research applications as to impact on the cancer patient community on diagnosis, treatment, prognosis, etc.  It is also rewarding to participate on the “flipside” of what we seek to achieve via our Advocacy Day efforts: Cancer research funding.”

Consumer advocates and scientists have worked together in this unique partnership to evaluate the merit of research applications since FY09. COL Sarah B. Goldman, Director of the CDMRP, expressed her appreciation for the consumer advocates’ hard work. “Integrating consumer perspectives into our decision-making process brings energy and focus to our research programs.  Patients, caregivers, family members, and advocates help us keep our efforts centered around what is truly important to those impacted.  We very much value this critical input from our consumers who help ensure that CDMRP’s work remains critical and relevant,” she said.

Scientists applying propose to support and promote high-impact research for cancer prevention, detection, treatment, quality of life and survivorship, and decreasing the burden of cancer on Service members, their families and the American public. The PRCRP fills important gaps not addressed by other funding agencies by supporting groundbreaking research while encouraging out-of-the-box thinking.

More information about the CDMRP’s PRCRP is available at the website:

Optional: Attached is a recent digital photograph provided by Amy Jacobs that may be used in conjunction with this press release.  


Media Contact:

Kate Poindexter 

Public Affairs Specialist 

Ripple Effect 

Supporting the Congressionally Directed Medical Research Programs,



November 29, 2022 – NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of nivolumab (Opdivo) plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.1

Read more>

November 25, 2022 – S’pore firm comes up with world’s first molecular blood test for early detection of gastric cancer

SINGAPORE – When Associate Professor Too Heng-Phon was about to start biotechnology firm Mirxes back in 2010, he asked several of his PhD students to join him, but also warned them that it would be tough going.

Two of them decided to help set up the home-grown biotech firm, which went on to develop test kits that use blood-based microRNAs (miRNAs) to serve as biomarkers for early detection of cancers.

Read more>